Drug application
SUMATRIPTAN SUCCINATE (SUMATRIPTAN SUCCINATE)
Drugs@FDA ANDA 207101 · BAXTER HLTHCARE CORP
Key facts
| Drug name | SUMATRIPTAN SUCCINATE |
|---|---|
| Active ingredients | SUMATRIPTAN SUCCINATE |
| Application type | ANDA |
| Application number | 207101 |
| Company | BAXTER HLTHCARE CORP |
| Dosage forms | SOLUTION, SUBCUTANEOUS |
| Strength | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) |
| Marketing status | Discontinued |
| TE codes | AP |
| Reference listed drug | No |
| Latest submission status date | Jan 19, 2023 |
At a glance
- 1–9 Submissions
- None Label versions
- 1–9 Products
- 10–99 Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.